IHT Wealth Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

IHT Wealth Management’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-18,890	Closed	-$31K	–	817
2022 Q1	$31K	Hold	18,890	–	–	﹤0.01%	751
2021 Q4	$45K	Sell	18,890 -1,280	-6%	-$5.21K	﹤0.01%	789
2021 Q3	$110K	Buy	20,170 +850	+4%	+$5.27K	0.01%	772
2021 Q2	$144K	Buy	+19,320	New	+$137K	0.01%	898
2020 Q1	–	Sell	-13,400	Closed	-$67K	–	662
2019 Q4	$67K	Buy	13,400 +2,450	+22%	+$15.6K	0.01%	608
2019 Q3	$82K	Buy	+10,950	New	+$95.1K	0.01%	592

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

IHT Wealth Management's KLDO Position: Q2 2022 in Review

IHT Wealth Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 18,890 shares — an estimated $31K sold.

IHT Wealth Management first reported a position in KLDO in Q3 2019 and held it in 6 quarters. The position peaked at $144K in Q2 2021. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

IHT Wealth Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
IHT Wealth Management sold 18,890 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $31K.
IHT Wealth Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q3 2019 and held it in 6 quarters.
IHT Wealth Management's Kaleido Biosciences, Inc. Common Stock position peaked at $144K in Q2 2021.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on IHT Wealth Management's 13F filing for Q2 2022, filed 15 Aug 2022.